These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 21641899

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T.
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [Abstract] [Full Text] [Related]

  • 3. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
    Gulati AP, Saif MW.
    Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M, Moneada M M, Tapia N G, Méndez O G, Galindo A H, Huete G A, Ibáñez A L, González S, Alvarez Z M.
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
    Ando Y, Tsunoda T, Beck Y, Takayama T, Tahara H.
    Surg Today; 2005 Oct; 35(2):157-60. PubMed ID: 15674500
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK, Jebsen NL, Mannelqvist M, Skar R, Eide J, Øvrebø K, Horn A, Jensen DK, Monge OR, Lilleng PK.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):868-72. PubMed ID: 15815732
    [Abstract] [Full Text] [Related]

  • 8. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 07; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
    Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF.
    J Surg Oncol; 2010 Nov 01; 102(6):599-603. PubMed ID: 20976730
    [Abstract] [Full Text] [Related]

  • 11. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R.
    Histopathology; 2005 Jul 01; 47(1):41-7. PubMed ID: 15982322
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
    Bar-Sela G, Lev LM, Kuten A, Wollner M, Haim N.
    Harefuah; 2006 Jan 01; 145(1):2-7, 80. PubMed ID: 16450715
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK.
    Cancer; 2006 Nov 01; 107(9):2237-44. PubMed ID: 16998931
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2004 Nov 01; 26(11):697-9. PubMed ID: 15777512
    [Abstract] [Full Text] [Related]

  • 20. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor.
    Gerin F, Baloglu O, Morgan JA, Kesari S.
    J Neurooncol; 2007 Apr 01; 82(2):227-8. PubMed ID: 17106648
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.